To evaluate the prognostic value of soluble immune checkpoints and immune regulators in previously treated lung cancer in patients receiving anti PD-L1/PD1 single agents
Latest Information Update: 26 May 2021
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
Most Recent Events
- 26 May 2021 New trial record
- 10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research